Advanced search
1 file | 3.53 MB Add to list

Association of polypharmacy and hyperpolypharmacy with frailty states : a systematic review and meta-analysis

Author
Organization
Abstract
Purpose: To investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. We searched PubMed, Web of Science, and Embase from 01/01/1998 to 5/2/2018. Pooled estimates were obtained through random effect models and Mantel-Haenszel weighting. Homogeneity was assessed with the I-2 statistic and publication bias with Egger's and Begg's tests. Results: Thirty-seven studies were included. The pooled proportion of polypharmacy in persons with prefrailty and frailty was 47% (95% CI 33-61) and 59% (95% CI 42-76), respectively. Increased odds ratio of polypharmacy were seen for prefrail (pooled OR=1.52; 95% CI 1.32-1.79) and frail persons (pooled OR=2.62, 95% CI 1.81-3.79). Hyperpolypharmacy was also increased in prefrail (OR=1.95; 95% CI 1.41-2.70) and frail (OR=6.57; 95% CI 9.57-10.48) persons compared to robust persons. Only seven longitudinal studies reported data on the risk of either incident prefrailty or frailty in persons with baseline polypharmacy. A significant higher odds of developing prefrailty was found in robust persons with polypharmacy (pooled OR=1.30; 95% CI 1.12-1.51). We found no papers investigating polypharmacy incidence in persons with prefrailty/frailty. Conclusions: Polypharmacy is common in prefrail and frail persons, and these individuals are also more likely to be on extreme drug regimens, i.e. hyperpolypharmacy, than robust older persons. More research is needed to investigate the causal relationship between polypharmacy and frailty syndromes, thereby identifying ways to jointly reduce drug burden and prefrailty/frailty in these individuals.Prospero registration numberCRD42018104756.
Keywords
Frail, Prefrail, Polypharmacy, Drugs, Ageing, Medications, Hyperpolypharmacy, OLDER-PEOPLE, ELDERLY-PATIENTS, PREVALENCE, HEALTH, RISK, ADULTS, MEN, COMMUNITIES, TRANSITIONS, INPATIENTS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.53 MB

Citation

Please use this url to cite or link to this publication:

MLA
Palmer, Katie et al. “Association of Polypharmacy and Hyperpolypharmacy with Frailty States : a Systematic Review and Meta-analysis.” EUROPEAN GERIATRIC MEDICINE 10.1 (2019): 9–36. Print.
APA
Palmer, K., Villani, E. R., Vetrano, D. L., Cherubini, A., Cruz-Jentoft, A. J., Curtin, D., Denkinger, M., et al. (2019). Association of polypharmacy and hyperpolypharmacy with frailty states : a systematic review and meta-analysis. EUROPEAN GERIATRIC MEDICINE, 10(1), 9–36.
Chicago author-date
Palmer, Katie, Emanuele R Villani, Davide L Vetrano, Antonio Cherubini, Alfonso J Cruz-Jentoft, Denis Curtin, Michael Denkinger, et al. 2019. “Association of Polypharmacy and Hyperpolypharmacy with Frailty States : a Systematic Review and Meta-analysis.” European Geriatric Medicine 10 (1): 9–36.
Chicago author-date (all authors)
Palmer, Katie, Emanuele R Villani, Davide L Vetrano, Antonio Cherubini, Alfonso J Cruz-Jentoft, Denis Curtin, Michael Denkinger, Marta Gutiérrez-Valencia, Adalsteinn Guðmundsson, Wilma Knol, Diane V Mak, Denis O’Mahony, Farhad Pazan, Mirko Petrovic, Chakravarthi Rajkumar, Eva Topinkova, Catarina Trevisan, Tischa JM van der Cammen, Rob J van Marum, Martin Wehling, Gijsbertus Ziere, Roberto Bernabei, and Graziano Onder. 2019. “Association of Polypharmacy and Hyperpolypharmacy with Frailty States : a Systematic Review and Meta-analysis.” European Geriatric Medicine 10 (1): 9–36.
Vancouver
1.
Palmer K, Villani ER, Vetrano DL, Cherubini A, Cruz-Jentoft AJ, Curtin D, et al. Association of polypharmacy and hyperpolypharmacy with frailty states : a systematic review and meta-analysis. EUROPEAN GERIATRIC MEDICINE. 2019;10(1):9–36.
IEEE
[1]
K. Palmer et al., “Association of polypharmacy and hyperpolypharmacy with frailty states : a systematic review and meta-analysis,” EUROPEAN GERIATRIC MEDICINE, vol. 10, no. 1, pp. 9–36, 2019.
@article{8580512,
  abstract     = {Purpose: To investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa.
Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. We searched PubMed, Web of Science, and Embase from 01/01/1998 to 5/2/2018. Pooled estimates were obtained through random effect models and Mantel-Haenszel weighting. Homogeneity was assessed with the I-2 statistic and publication bias with Egger's and Begg's tests.
Results: Thirty-seven studies were included. The pooled proportion of polypharmacy in persons with prefrailty and frailty was 47% (95% CI 33-61) and 59% (95% CI 42-76), respectively. Increased odds ratio of polypharmacy were seen for prefrail (pooled OR=1.52; 95% CI 1.32-1.79) and frail persons (pooled OR=2.62, 95% CI 1.81-3.79). Hyperpolypharmacy was also increased in prefrail (OR=1.95; 95% CI 1.41-2.70) and frail (OR=6.57; 95% CI 9.57-10.48) persons compared to robust persons. Only seven longitudinal studies reported data on the risk of either incident prefrailty or frailty in persons with baseline polypharmacy. A significant higher odds of developing prefrailty was found in robust persons with polypharmacy (pooled OR=1.30; 95% CI 1.12-1.51). We found no papers investigating polypharmacy incidence in persons with prefrailty/frailty.
Conclusions: Polypharmacy is common in prefrail and frail persons, and these individuals are also more likely to be on extreme drug regimens, i.e. hyperpolypharmacy, than robust older persons. More research is needed to investigate the causal relationship between polypharmacy and frailty syndromes, thereby identifying ways to jointly reduce drug burden and prefrailty/frailty in these individuals.Prospero registration numberCRD42018104756.},
  author       = {Palmer, Katie and Villani, Emanuele R and Vetrano, Davide L and Cherubini, Antonio and Cruz-Jentoft, Alfonso J and Curtin, Denis and Denkinger, Michael and Gutiérrez-Valencia, Marta and Guðmundsson, Adalsteinn and Knol, Wilma and Mak, Diane V and O’Mahony, Denis and Pazan, Farhad and Petrovic, Mirko and Rajkumar, Chakravarthi and Topinkova, Eva and Trevisan, Catarina and van der Cammen, Tischa JM and van Marum, Rob J and Wehling, Martin and Ziere, Gijsbertus and Bernabei, Roberto and Onder, Graziano},
  issn         = {1878-7649},
  journal      = {EUROPEAN GERIATRIC MEDICINE},
  keywords     = {Frail,Prefrail,Polypharmacy,Drugs,Ageing,Medications,Hyperpolypharmacy,OLDER-PEOPLE,ELDERLY-PATIENTS,PREVALENCE,HEALTH,RISK,ADULTS,MEN,COMMUNITIES,TRANSITIONS,INPATIENTS},
  language     = {eng},
  number       = {1},
  pages        = {9--36},
  title        = {Association of polypharmacy and hyperpolypharmacy with frailty states : a systematic review and meta-analysis},
  url          = {http://dx.doi.org/10.1007/s41999-018-0124-5},
  volume       = {10},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: